Supplementary Figure 5 (Related to Figure 3)



Supplementary Figure 5. Related to Figure 3. PRMT1V2 activates hepatic gluconeogenesis through PGC1α. *A*) Schematic of the experiment. *Prmt1*$^{fl/fl}$ mice were injected with indicated adenovirus through tail vein for CRE-mediated deletion. Seven days after first injection, the mice were injected with indicated adenoviruses through tail vein for knockdown of *Ppargc1a*. *B*) qPCR analyses of *Ppargc1a*, *P1V1*, *P1V2*, and gluconeogenic marker mRNA levels in primary hepatocytes isolated from mice described in (*A*) and infected with indicated adenoviruses (n = 4/group). *C*) Blood glucose levels of 16 hour-fasted *Prmt1*$^{fl/fl}$ and *Alb-Cre*;*Prmt1*$^{fl/fl}$ injected with indicated adenoviruses (n = 5 for *Prmt1*$^{fl/fl}$, n = 4 for *Alb-Cre*;*Prmt1*$^{fl/fl}$). *D*) qPCR analyses of *Prmt1* and gluconeogenic marker mRNA levels in the liver of 16 hour-fasted mice described in (*C*) (n = 5 for *Prmt1*$^{fl/fl}$, n = 4 for *Alb-Cre*;*Prmt1*$^{fl/fl}$). *E*) PTT in 16 hour-fasted mice described in (*C*) (n = 5 for *Prmt1*$^{fl/fl}$, n = 4 for *Alb-Cre*;*Prmt1*$^{fl/fl}$). AUC, area under the curve. Data are presented as mean ± SEM. **P* < 0.05; ***P* < 0.01; ****P* < 0.001. n.s., not significant. 2-way ANOVA (B-E).